Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264307 | 1.00 | LMNA (0.44) | LMNAALDH1A1KMT2AMAPTTAAR1 | |
| SCHEMBL1663724 | 0.90 | LMNA (0.39) | LMNAALDH1A1KMT2AMAPTTSHR | |
| SCHEMBL23064871 | 0.90 | LMNA (0.39) | LMNAALDH1A1KMT2AMAPTTAAR1 | |
| SCHEMBL14433686 | 0.87 | LMNA (0.52) | LMNAALDH1A1KMT2AMAPTTAAR1 | |
| SCHEMBL1004125 | 0.87 | LMNA (0.52) | LMNAALDH1A1KMT2AMAPTTAAR1 | |
| SCHEMBL3031493 | 0.87 | LMNA (0.52) | LMNAALDH1A1KMT2AMAPTTAAR1 | |
| SCHEMBL187221 | 0.87 | LMNA (0.52) | LMNAALDH1A1KMT2AMAPTTAAR1 | |
| SCHEMBL23176525 | 0.87 | LMNA (0.52) | LMNAALDH1A1KMT2AMAPTTAAR1 | |
| SCHEMBL3045980 | 0.87 | LMNA (0.52) | LMNAALDH1A1KMT2AMAPTTAAR1 | |
| SCHEMBL23698034 | 0.87 | LMNA (0.52) | LMNAALDH1A1KMT2AMAPTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597390-B2 | Indoles for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2020-03-24 | — | — | US | disclosed |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2013-11-14 | — | — | US | disclosed |
| EP-2601187-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | Conrig Pharma ApS (DK) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012016569-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | HTR1A, HTR1D, HTR5A | LMNA 3435/4885ALDH1A1 620/4885KMT2A 3290/4885 |
| US-10597390-B2 | Indoles for use in influenza virus infection | IDO1, IDO2, INMT | LMNA 3745/4885ALDH1A1 143/4885KMT2A 618/4885 |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | IDO1, IDO2, INMT | LMNA 3745/4885ALDH1A1 143/4885KMT2A 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.